These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 8671669)

  • 1. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease.
    Sugita S; Sagawa K; Mochizuki M; Shichijo S; Itoh K
    Int Immunol; 1996 May; 8(5):799-803. PubMed ID: 8671669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ocular infiltrating CD 4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens].
    Sugita S
    Nippon Ganka Gakkai Zasshi; 2008 Nov; 112(11):953-64. PubMed ID: 19069378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
    Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
    J Immunol; 1996 Jan; 156(1):208-17. PubMed ID: 8598464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.
    Sugita S; Takase H; Taguchi C; Imai Y; Kamoi K; Kawaguchi T; Sugamoto Y; Futagami Y; Itoh K; Mochizuki M
    Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2547-54. PubMed ID: 16723469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.
    D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P
    Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
    van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
    Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
    Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G
    J Exp Med; 1993 Apr; 177(4):989-98. PubMed ID: 8459226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
    Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
    J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis.
    Damico FM; Cunha-Neto E; Goldberg AC; Iwai LK; Marin ML; Hammer J; Kalil J; Yamamoto JH
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2465-71. PubMed ID: 15980237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient.
    Abad S; Wieërs G; Colau D; Wildmann C; Delair E; Dhote R; Brézin AP; Kawakami Y; Coulie PG; van der Bruggen P
    Mol Vis; 2014; 20():956-69. PubMed ID: 24991188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.
    Maeurer MJ; Necker A; Salter RD; Castelli C; Höhn H; Karbach J; Freitag K; Neukirch C; Knuth A; Jäger E
    Int J Cancer; 2002 Jan; 97(1):64-71. PubMed ID: 11774245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
    Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
    Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
    Murray JL; Hudson JM; Ross MI; Zhang HZ; Ioannides CG
    J Immunother; 2000 Jan; 23(1):28-35. PubMed ID: 10687135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.
    Fleischhauer K; Tanzarella S; Wallny HJ; Bordignon C; Traversari C
    J Immunol; 1996 Jul; 157(2):787-97. PubMed ID: 8752930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.